有关恶性淋巴瘤每种亚型中积累的基因突变的信息已有报道。预计突变的鉴定不仅对于明确诊断变得更加重要，而且对于选择有效的靶向治疗和分析可检测的残留疾病也变得更加重要。然而，在恶性淋巴瘤的临床环境中，DNA样本可能很难获得，并且与白血病部门相比，在整个疾病发展和/或缓解过程中纵向样本收集极其困难。液体活检是肿瘤活检的一种新策略，可从患者血浆、脑脊液或其他体液中检测异常的肿瘤衍生基因。随着遗传分析方法的进步，关于液体活检在弥漫性大 B 细胞淋巴瘤、中枢神经系统淋巴瘤、霍奇金淋巴瘤和其他类型淋巴瘤中的有效性的报道越来越多。该方法有可能显着改变日常实践中ML诊断和随访的方式，其发展备受关注。

Information about genetic mutations that accumulate in each subtype of malignant lymphoma has been reported. Identification of mutations is predicted to become more crucial not only for a definitive diagnosis but also for selecting effective targeted therapies and analyzing detectable residual diseases. However, in the clinical environment of malignant lymphoma, DNA samples might be difficult to obtain, and longitudinal sample collection throughout disease development and/or remission is exceedingly difficult compared to leukemia sectors. Liquid biopsy is a new strategy of tumor biopsy that detects aberrant tumor-derived genes from a patient's plasma, cerebrospinal fluid, or other body fluids. With advances in genetic analysis methods, reports are accumulating on the usefulness of liquid biopsy in diffuse large B-cell lymphoma, central nerves system lymphoma, Hodgkin lymphoma, and other types of lymphoma. This method has the potential to significantly change the way of ML diagnosis and followed up in daily practice, and its development is a great deal of attention.